Full Breakdown
Jalen Hurts’ Blood-Clot Diagnosis, London Play, and the NFL-NFLPA Joint Review
By Drooid · · How we work
In this breakdown
01
Core Event
Philadelphia Eagles quarterback Jalen Hurts was diagnosed with a superficial vein thrombosis in his left calf while the team was in London for its Week 5 matchup against the Jacksonville Jaguars on October 11, 2026. He completed 21 of 40 passes for 220 yards in a 19-17 loss. Imaging later showed the clot had migrated, leading to a diagnosis of deep-vein thrombosis and bilateral pulmonary emboli. Hurts was placed on injured reserve and is expected to miss the remainder of the season.
02
Background & Context
The clotting episode began after Hurts was struck in the calf by a cleat during the October 4, 2026 loss to the Los Angeles Rams. He reported discomfort on October 8 and resumed practice before traveling to London. Specialists there identified a “stable superficial clot,” a lower-risk condition than DVT because it lies near the skin’s surface. Anticoagulant therapy is typically reserved for DVT due to the risk of pulmonary embolism.
Visual evidence
Images from the story
03
Timeline
Swipe across the table to see all columns.
| Date | Event |
|---|---|
| Oct 4, 2026 | Hurts takes a cleat to the calf. |
| Oct 8, 2026 | Reports discomfort; practices next day. |
| Oct 10, 2026 | Ultrasound in London detects a superficial clot; cleared to play. |
| Oct 11, 2026 | Starts and finishes the Jaguars game. |
| Oct 14, 2026 | Follow-up imaging shows clot migration (reported). |
| Oct 19, 2026 | Testing confirms DVT and pulmonary emboli; placed on IR. |
| Oct 21, 2026 | NFL chief medical officer Dr. Allen Sills: “all protocols were followed.” |
| Oct 25, 2026 | Joint NFL-NFLPA statement announces a collaborative review. |
04
Data & Statistics
- Contract: Five-year extension worth $255 million through 2028.
- Medical findings: Progression from superficial vein thrombosis to DVT and bilateral pulmonary emboli.
- London performance: 21/40 completions, 220 yards, 1 TD.
05
Official Statements & Responses
- The Eagles and Hurts’ agent Nicole Lynn confirmed the DVT and pulmonary emboli diagnosis and that Hurts will remain on blood-thinners, which prohibit contact play.
- Dr. Allen Sills asserted that “all protocols were followed.”
- The NFLPA demanded a “full investigation” into whether the medical evaluation met CBA standards.
06
On-the-Ground Reports
Hurts described the London experience as “very unique” but gave no medical details. Coach Nick Sirianni declined to discuss the decision-making, citing lack of medical expertise.
07
Conflicting Reports & Gaps
- Some outlets say follow-up imaging on Oct 14 already showed clot movement, while other sources list that date as “scheduled,” creating uncertainty about when the imaging occurred.
- Precise ultrasound findings that led to the initial superficial diagnosis have not been released; Dr. Chuck Dinerstein noted the “exact findings” remain unknown.
08
What’s Next
The joint NFL-NFLPA review, set for Oct 25, 2026, will examine the medical timeline, the clearance decision, and flight precautions. Findings may prompt revisions to league medical guidelines or CBA grievance procedures.